Company intelligence / Profile preview

Immune-Onc Therapeutics

Palo Alto, California, United Statesimmune-onc.com ↗

Ownership: Private
Development stage: Phase 1

Overview

IO-108 has demonstrated promising clinical efficacy as a single agent with a well-established safety profile in combination with different standard of care regimens. IO-202 is in Phase 1b clinical development for AML and CMML.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodiesBispecific antibodies
Industry: Biotech

Drug pipeline

7 assets

IO-108

6 more assets in the full pipeline.

Request access →

Partnerships

RocheBeiGeneRegeneronThe University of Texas Health Science Center at HoustonThe University of Texas Southwestern Medical Center

Beyond the preview

Go deeper on Immune-Onc Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune-Onc Therapeutics.

Explore the full profile